Asthma :: Even occasional use of spray cleaners may cause asthma in adults

Using household cleaning sprays and air fresheners as little as once a week can raise the risk of developing asthma in adults, say researchers in Europe. Such products have been associated with increased asthma rates in cleaning professionals, but a similar effect in nonprofessional users has never before been shown.

Multiple Sclerosis :: Accentia announces investigational new drug application for Revimmune for refractory MS

Accentia Biopharmaceuticals announces that it met with the Food and Drug Administration (FDA) on September_26, 2007 for a scheduled pre-Investigational New Drug (pre-IND) meeting on Revimmune™. The FDA has indicated its support for Accentia to submit an IND for a pivotal Phase 3 randomized controlled, multi-center clinical trial of Revimmune, the company’s potential therapeutic for refractory, relapsing-remitting Multiple Sclerosis (MS).

Health :: NAS Report Offers New Tools to Assess Health Risks from Chemicals

Determining how thousands of chemicals found in the environment may be interacting with the genes in your body to cause disease is becoming easier because of a new field of science called toxicogenomics. A new report issued today by the National Academies of Sciences (NAS) recognizes the importance of toxicogenomics in predicting effects on human health and recommends the integration of toxicogenomics into regulatory decision making.

Clinical Trial :: Paving the way for future pan-European clinical trials

Pan-European collaboration is important for many clinical trials and essential for trials that are investigating treatments for rare diseases. That was the message delivered today by the European Medical Research Councils (EMRC), the membership organisation for medical research councils across Europe based at the European Science Foundation (ESF) in Strasbourg, which is coordinating two trials in rare diseases and about to launch a review of how best to implement clinical trials that are initiated by investigators.